Skip to main content
Johnson & JohnsonIntegration

J&J’s Bispecific Drug Wins Fast FDA Approval for Head and Neck Cancer

Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.

What happened

Johnson & Johnson uses drug-delivery technology developed by Halozyme for subcutaneous administration of Rybrevant Faspro.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Johnson & Johnson (J&J) has received accelerated US Food and Drug Administration (FDA) approval for its bispecific antibody drug, Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), to treat adults with advanced head and neck squamous cell carcinoma (HNSCC). The approval offers a new treatment option for patients whose cancer has progressed despite standard chemotherapy and immunotherapy. This latest approval expands the drug's use beyond lung cancer, where Rybrevant was initially approved in 2021 for certain cases of non-small cell lung cancer (NSCLC). Rybrevant is a bispecific antibody that targets two receptors, epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET). Both receptors can contribute to cancer growth and treatment resistance. By blocking these two targets simultaneously, the drug aims to prevent cancer cells from developing resistance to treatment. The therapy is designed for patients who have experienced disease progression during or after currently available standard treatments. Rybrevant Faspro uses drug-delivery technology developed by Halozyme, allowing healthcare professionals to administer the treatment through a subcutaneous injection rather than an intravenous infusion. The injectable formulation takes approximately five minutes to administer, compared with two to five hours for the intravenous version. This shorter...

Keep reading with a free account

The rest of this article, and every signal for Johnson & Johnson, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Integration

What this signalsA new integration often shows which tools the company builds around.

Product
Rybrevant Faspro

Companies

  • HalozymePartnerhalozyme.com

More integration signals at other companies

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
85%
Detected
Nov 9, 2026
signal_type
news
signal_subtype
integrates_with

Use this data

Get every integration signal for Johnson & Johnson and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”

  2. Send it to your own tools

    The Signal API returns integration signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b425eb03-abee-e0cc-838e-733f347e1f64 returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.

{
  "signal_id": "b425eb03-abee-e0cc-838e-733f347e1f64",
  "signal_type": "news",
  "signal_subtype": "integrates_with",
  "detected_at": "2026-11-09T10:09:47+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://theindianpractitioner.com/jjs-bispecific-drug-wins-fast-fda-approval-for-head-and-neck-cancer/",
    "title": "J&J’s Bispecific Drug Wins Fast FDA Approval for Head and Neck Cancer - The Indian Practitioner",
    "excerpt": "Johnson & Johnson (J&J) has received accelerated US Food and Drug Administration (FDA) approval for its bispecific antibody drug, Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), to treat adults with advanced head and neck squamous cell carcinoma (HNSCC). The approval offers a new treatment option for patients whose cancer has progressed despite standard chemotherapy and immunotherapy. This latest approval expands the drug’s use beyond lung cancer, where Rybrevant was initially approved in 2021 for certain cases of non-small cell lung cancer (NSCLC). Rybrevant is a bispecific antibody that targets two receptors, epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET). Both receptors can contribute to cancer growth and treatment resistance. By blocking these two targets simultaneously, the drug aims to prevent cancer cells from developing resistance to treatment. The therapy is designed for patients who have experienced disease progression during or after currently available standard treatments. Rybrevant Faspro uses drug-delivery technology developed by Halozyme, allowing healthcare professionals to administer the treatment through a subcutaneous injection rather than an intravenous infusion. The injectable formulation takes approximately five minutes to administer, compared with two to five hours for the intravenous version. This shorter...",
    "product": "Rybrevant Faspro",
    "summary": "Johnson & Johnson uses drug-delivery technology developed by Halozyme for subcutaneous administration of Rybrevant Faspro.",
    "planning": false,
    "image_url": "https://theindianpractitioner.com/wp-content/uploads/2026/11/JJ-Bispecific-Drug-Wins-Fast-FDA-Approval-for-Head-and-Neck-Cancer-scaled.jpg",
    "confidence": 0.85,
    "product_data": {
      "name": "Rybrevant Faspro",
      "full_text": "bispecific antibody drug, Rybrevant Faspro",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-11-09T10:09:47Z",
    "article_sentence": "Rybrevant Faspro uses drug-delivery technology developed by Halozyme, allowing healthcare professionals to administer the treatment through a subcutaneous injection rather than an intravenous infusion.",
    "related_company_name": "Halozyme",
    "related_company_domain": "halozyme.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.